Russian COVID-19 vaccine Sputnik's single-dose jab Sputnik Light has received Drugs Controller General of India's (DCGI) nod to conduct phase-3 bridging trials in India.
DCGI's Subject Expert Committee (SEC) recommended the phase-3 bridging trials for the vaccine. The
SEC had in July refused to grant emergency use authorisation (EUA) to Sputnik Light, precluding the need for the conduct of the phase-3 trial of the Russian COVID-19 vaccine in the country.
According to a recent study published in The Lancet, Sputnik Light demonstrated 78.6-83.7% efficacy against COVID-19, considerably higher than most two-shot jabs.
The study was carried out on around 40,000 elderly population in Argentina. It also showed that Sputnik Light lessened hospitalisations among the target population at 82.1-87.6%.
Russia started human trials of Sputnik Light in January this year. The country's authorities gave regulatory approval to the jab in May.
The single-shot vaccine has been developed by Russia's Gamaleya Institute and backed by the Russian Direct Investment Fund (RDIF), which is the country's sovereign wealth fund.
Copyright©2021 Living Media India Limited. For reprint rights: Syndications Today